News
StockStory.org on MSN2h
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue EstimatesHealthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its ...
The US initiated a Section 232 investigation on pharmaceutical products in April, purportedly to verify the impact of imports ...
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...
Risk assessment for potential mutagenic side-products is still required by regulatory bodies, despite lack of evidence they ...
The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...
The Canadian pharmaceutical industry is still waiting to learn about tariffs as high as 200 per cent on exports to the U.S.
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...
US President Donald Trump on Tuesday warned of a whopping 250% tariffs on the pharma industry one year, one-and-a-half years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback